Literature DB >> 31881091

Associations Between Migraine and Adverse Pregnancy Outcomes: Systematic Review and Meta-analysis.

Annet M Aukes1, Feyza N Yurtsever2, Amélie Boutin3, Marieke C Visser4, Christianne J M de Groot5.   

Abstract

IMPORTANCE: Migraine is a highly prevalent disorder associated with cardiovascular diseases. Cardiovascular diseases are also associated with preeclampsia (PE). The adverse pregnancy outcomes PE, preterm birth (PTB), low birth weight (LBW), small for gestational age (SGA) and placental abruption share aspects in their pathophysiology, which are also found in patients with migraine, such as inflammatory stress and hypercoagulability.
OBJECTIVE: To determine the association of adverse pregnancy outcomes including PE, PTB, LBW, SGA, and placental abruption with a history of migraine through a systematic review and meta-analysis. EVIDENCE ACQUISITION: MEDLINE (PubMed), the Cochrane Library, and EMBASE, were searched from inception to November 11, 2018. Cohort studies and case-control studies evaluating migraine history and pregnancy complications were eligible.
RESULTS: Of 1388 screened references, 14 studies were included in the systematic review. There were higher risks of PE (odds ratio [OR], 2.07; 95% confidence interval [CI], 1.51-2.85; I2 = 76%) and LBW (OR, 1.18; 95% CI, 1.03-1.34; I2 = 9%) in women with migraine compared with women without migraine. We observed no significant association between history of migraine and PTB (OR, 1.23; 95% CI, 0.97-1.55; I2 = 61%) or SGA (OR, 1.06; 95% CI, 0.98-1.15; I2 = 0%).
CONCLUSIONS: A history of migraine is significantly associated with an increased risk of adverse pregnancy outcomes including PE and LBW. We hypothesize that shared pathophysiology due to underlying preclinical cardiovascular risk in women with migraine might play a role during pregnancy. RELEVANCE: Pregnant women with a history of migraine should be considered at higher risk of adverse pregnancy outcomes and should be informed, monitored, and treated preventively accordingly.

Entities:  

Mesh:

Year:  2019        PMID: 31881091     DOI: 10.1097/OGX.0000000000000738

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  6 in total

1.  Population-Based Study of Nonelective Postpartum Readmissions in Women With Stroke, Migraine, Multiple Sclerosis, and Myasthenia Gravis.

Authors:  Barbara M Decker; Dylan Thibault; Kathryn A Davis; Allison W Willis
Journal:  Neurology       Date:  2022-02-15       Impact factor: 11.800

2.  Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association.

Authors:  Vesna D Garovic; Ralf Dechend; Thomas Easterling; S Ananth Karumanchi; Suzanne McMurtry Baird; Laura A Magee; Sarosh Rana; Jane V Vermunt; Phyllis August
Journal:  Hypertension       Date:  2021-12-15       Impact factor: 9.897

3.  Epidemiology, Risk Factors, and Perinatal Outcomes of Placental Abruption-Detailed Annual Data and Clinical Perspectives from Polish Tertiary Center.

Authors:  Monika Bączkowska; Katarzyna Kosińska-Kaczyńska; Magdalena Zgliczyńska; Robert Brawura-Biskupski-Samaha; Beata Rebizant; Michał Ciebiera
Journal:  Int J Environ Res Public Health       Date:  2022-04-23       Impact factor: 4.614

4.  De novo Migraine with Aura in the Third Trimester of Pregnancy: A Case Report and Literature review.

Authors:  Elena Paškevičiūtė; Diana Bužinskienė; Kristina Ryliškienė
Journal:  Acta Med Litu       Date:  2021-05-11

5.  Migraine and Medical Ramifications: A Comprehensive Overview Based on Observational Study Meta-Analyses.

Authors:  Weiwei Chen; Wenqi Qian; Lixian Zhong; Gongwei Jing
Journal:  Front Neurol       Date:  2021-12-24       Impact factor: 4.003

6.  Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes.

Authors:  Anick Bérard; Shannon Strom; Jin-Ping Zhao; Shashi Kori; Detlef Albrecht
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.